Abstract Details

Title Analytical and Clinical Assessment of Plasma Phospho-Tau Isoforms in Alzheimer’s Disease (AD)

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) S15 - Innovative Diagnostics in Dementia (2:00 PM-2:12 PM)

Poster/Presentation
Number 006

Background

Highly phosphorylated Tau protein is a major component of neurofibrillary tangles, a primary AD neuropathological cortical marker. Recently, sensitive immunoassays capable of measuring p-Tau isoforms p-Tau217 and p-Tau181 in blood have been developed, with promising diagnostic potential for AD.

Objective Evaluate the analytical and clinical performance of four p-Tau assays using plasma from AD subjects and healthy controls, and determine correlative and discriminatory relationships for each assay and clinical diagnosis group.

Design/Methods

AD plasma (n=64) and healthy control plasma (n=25) were analyzed with Simoa p-Tau217 developed by Alzpath, p-Tau181V2 and p-Tau181V2.1 (Quanterix) immunoassays using the HD-X analyzer, and the Lumipulse p-Tau181 (Fujirebio) immunoassay using the G1200 system. Plasma p-Tau levels were evaluated within AD sample groups consisting of mild (n=16, MMSE >23-30), moderate (n=20, MMSE=16-22) and severe (n=28, MMSE<16) cognitive impairment, and healthy controls (n=25).

Results P-tau levels were detectable by the four assays in >95% of all samples. Analysis by the three p-Tau181 and one p-Tau217 assays revealed significant increases in median p-Tau levels in the combined AD group (2.5-4.4-fold; p<0.0001, n = 64), relative to controls (n=25), and group discrimination (ROC-AUC=0.92). Significant median p-Tau elevations of 2.8-8.5 fold were observed in the moderate and severe dementia groups (p <0.0001) and 1.3-1.8 fold in the mild dementia group (p=0.0001-0.003), although distributions overlapped. Moderate or severe dementia group discrimination from controls was more pronounced (AUC>0.95) compared to mild dementia (AUC=0.75-0.84). Moderate to strong correlations between the p-Tau levels measured by the four assays were observed (Pearson r = 0.7-0.9).

Conclusions

All p-Tau measurements were significantly elevated in the plasma of mild, moderate, and severe AD groups. All four p-Tau assays demonstrated robust analytical performance, and clinically differentiated AD plasma from healthy control plasma (p<0.0001). Plasma p-Tau181 and p-Tau217 biomarkers provide a practical diagnostic opportunity to identify AD patients.

Authors/Disclosures
Ahmed Chenna, PhD (Monogram Biosciences Inc) PRESENTER	Dr. Chenna has received personal compensation for serving as an employee of LabCorp-monogram Biosciences. Dr. Chenna has stock in LabCorp.
Andreas Jeromin, PhD (Quanterix Corp.)	Dr. Jeromin has received personal compensation for serving as an employee of AlzPath, Inc. Dr. Jeromin has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quanterx.
Brandon Yee (Monogram Biosciences/LabCorp)	Brandon Yee has received personal compensation for serving as an employee of Labcorp. Brandon Yee has stock in Lacborp.
Youssouf Badal	Youssouf Badal has nothing to disclose.
	No disclosure on file
Christos J. Petropoulos, PhD (Monogram Biosciences, LabCorp)	Dr. Petropoulos has received personal compensation for serving as an employee of Labcorp-Monogram Biosciences. Dr. Petropoulos has stock in Laboratory Corporation of America Holdings. Dr. Petropoulos has received intellectual property interests from a discovery or technology relating to health care.
John Winslow, PhD (Monogram Biosciences Inc., Laboratory Corporation of America)	Dr. Winslow has received personal compensation for serving as an employee of Labcorp/Monogram Biosciences. Dr. Winslow has received personal compensation for serving as an employee of Labcorp/Monogram Biosciences. Dr. Winslow has stock in Labcorp. Dr. Winslow has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��